How does this study impact clinical practice?

• This study showed that the safety and tolerability profile of LY3437943 is similar to other agents from the incretin class, and further revealed insights into the PK and PD profiles.
• The PK of LY3437943 is dose-proportional and the half-life supports once-weekly dosing, which would be beneficial in clinical practice.
• There were further significant decreases in plasma glucose, HbA1c, and body weight.
• Further clinical evaluation of LY3437943 in T2D (NCT04867785) and obesity (NCT04881760), and further research into vital signs in Phase 2 and 3 studies, will help characterise the triple agonist further.